Eli Lilly and Company is launching an expanded access program to provide its experimental obesity drug, retatrutide, to a limited group of patients before formal federal approval, according to a company announcement first reported by STAT News.
Eligibility Criteria for Pre-Approval Retatrutide Access
To qualify for the pre-access program, patients must meet strict medical thresholds established by Eli Lilly in alignment with regulatory guidelines. According to company statements, applicants must be at least 18 years old and exhibit refractory obesity that persists despite maximum tolerated doses of currently approved weight-management therapies. In addition, candidates must suffer from no more than two severe or life-threatening obesity-related complications that are actively receiving medical management. Eli Lilly also mandates that eligible individuals cannot enroll in active clinical trials testing retatrutide or any comparable investigational treatment.
Clinical Trial Data and Metabolic Mechanism
Retatrutide is a multi-receptor agonist engineered to activate three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This triple-agonist design expands upon existing therapies like Eli Lilly’s Zepbound, which targets solely GLP-1 and GIP receptors. Clinical trial data released by the company in July demonstrated substantial efficacy in adults with severe obesity and established heart disease.
Regulatory Timeline and Next Steps
Food and Drug Administration (FDA) approval for retatrutide during the first quarter of next year, according to company announcements. Until regulatory review concludes, the expanded access program remains the sole mechanism for eligible patients outside of clinical trials to receive the authentic medication. Healthcare providers seeking treatment for qualifying individuals can submit review requests directly through the manufacturer’s established compassionate use channels.
Worth a look